Publication | Closed Access

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy

Bone DiseaseBone HealthOncologyGeneric PamidronateBreast Cancer PatientsOral IbandronateBreast CancerPharmacotherapyOsteoporosisMedicineRadiation OncologyOrthopaedic Surgery